Exelixis, INC. (EXEL) — SEC Filings

Overview

Exelixis, INC. (EXEL) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a DEFA14A filed on Apr 17, 2026: Exelixis, Inc. filed a Definitive Additional Materials (DEFA14A) on April 17, 2026, related to proxy solicitations. The filing, with SEC Accession Number 0001628280-26-025746, contains supplemental proxy materials for the company. Exelixis, Inc. is headquartered at 1851 Harbor Bay Parkway, Alameda,

Sentiment Summary

Across 27 filings, the sentiment breakdown is: 5 bullish, 22 neutral. The dominant filing sentiment for Exelixis, INC. is neutral.

Filing Type Overview

Exelixis, INC. (EXEL) has filed 1 DEFA14A, 12 8-K, 6 10-Q, 2 DEF 14A, 2 10-K, 1 SC 13D/A, 2 SC 13G/A, 1 SC 13G with the SEC between Jan 2024 to Apr 2026.

Filings by Year

2026 · 2025 · 2024

Recent Filings (27)

• Exelixis Files Supplemental Proxy Materials — DEFA14A · Apr 17, 2026 Risk: low
  Exelixis, Inc. filed a Definitive Additional Materials (DEFA14A) on April 17, 2026, related to proxy solicitations. The filing, with SEC Accession Number 000162
• 8-K Filing — 8-K · Nov 7, 2025
• Exelixis Q3 Net Income Soars 41% on Strong Product Sales — 10-Q · Nov 4, 2025 Risk: medium
  EXELIXIS, INC. reported a strong financial performance for the nine months ended September 30, 2025, with total revenues increasing to $1,721,463 thousand, up f
• Exelixis Announces Executive and Director Changes — 8-K · Aug 29, 2025 Risk: medium
  Exelixis, Inc. announced on August 29, 2025, changes in its board of directors and executive compensation arrangements. Specifically, the company reported the d
• Exelixis Q2 Revenue Jumps on Strong Product Sales — 10-Q · Jul 28, 2025 Risk: medium
  EXELIXIS, INC. reported product revenue of $415.0 million for the quarter ended July 4, 2025, a significant increase from $370.0 million in the prior-year quart
• Exelixis Files 8-K on Shareholder Votes — 8-K · Jun 2, 2025 Risk: low
  Exelixis, Inc. filed an 8-K on May 28, 2025, reporting on matters submitted to a vote of its security holders. The filing details the company's corporate action
• Exelixis, Inc. Files Q1 2025 10-Q Report — 10-Q · May 13, 2025 Risk: low
  Exelixis, Inc. filed its 10-Q for the period ending April 4, 2025. The company, based in Alameda, CA, operates in the biological products sector. Key financial
• Exelixis DEF 14A: Executive Pay & Equity Awards Detailed — DEF 14A · Apr 16, 2025 Risk: low
  Exelixis, Inc. filed its DEF 14A on April 16, 2025, detailing executive compensation and annual meeting matters for the fiscal year ending January 3, 2025. The
• Exelixis Announces Board & Executive Changes — 8-K · Mar 31, 2025 Risk: medium
  Exelixis, Inc. announced on March 31, 2025, changes in its board of directors and executive compensation. Specifically, the company reported the departure of ce
• Exelixis Files 8-K: Other Events & Exhibits — 8-K · Feb 21, 2025 Risk: low
  Exelixis, Inc. filed an 8-K on February 21, 2025, reporting events that occurred on February 20, 2025. The filing pertains to "Other Events" and "Financial Stat
• Exelixis, Inc. Files 2025 Fiscal Year 10-K Report — 10-K · Feb 11, 2025 Risk: medium
  Exelixis, Inc. filed its 10-K for the fiscal year ending January 3, 2025, reporting on its business operations and financial condition. The company, headquarter
• Exelixis, Inc. Files 8-K on Financials — 8-K · Jan 13, 2025 Risk: low
  Exelixis, Inc. filed an 8-K on January 13, 2025, reporting on its results of operations and financial condition as of January 12, 2025. The filing includes fina
• Exelixis Files 10-Q for Q3 2024 — 10-Q · Oct 29, 2024 Risk: medium
  Exelixis, Inc. filed its 10-Q for the period ending September 27, 2024. The company reported financial results and provided updates on its business operations.
• Exelixis, Inc. Files 8-K for Undisclosed Event — 8-K · Oct 15, 2024 Risk: medium
  On October 14, 2024, Exelixis, Inc. filed an 8-K report to disclose an "Other Event." The filing does not contain specific details about the event itself, but i
• Exelixis Files 10-Q for Q2 2024 — 10-Q · Aug 6, 2024 Risk: medium
  Exelixis, Inc. filed its 10-Q for the period ending June 28, 2024. The filing details financial performance and business operations, including revenue generated
• Exelixis Adds Two Directors to Board — 8-K · Jun 3, 2024 Risk: low
  Exelixis, Inc. announced on May 30, 2024, the election of Dr. Michelle Werner and Mr. David R. Johnson to its Board of Directors, effective immediately. Dr. Wer
• Exelixis, Inc. Files 8-K Report — 8-K · May 20, 2024 Risk: low
  On May 20, 2024, Exelixis, Inc. filed an 8-K report. The filing indicates that the company is providing information under "Other Events." Specific details regar
• Exelixis Acquires Kairos Therapeutics for $400M Upfront — 8-K · May 10, 2024 Risk: medium
  Exelixis, Inc. announced on May 9, 2024, that it has entered into a definitive agreement to acquire all outstanding shares of Kairos Therapeutics, Inc. for an u
• Farallon Capital Updates Exelixis Stake — SC 13D/A · May 8, 2024 Risk: medium
  Farallon Capital Partners, L.P. has amended its Schedule 13D filing regarding Exelixis, Inc. as of May 8, 2024. The filing indicates a change in beneficial owne
• Exelixis, Inc. Files 10-Q for Period Ending March 29, 2024 — 10-Q · Apr 30, 2024 Risk:
  EXELIXIS, INC. (EXEL) filed a Quarterly Report (10-Q) with the SEC on April 30, 2024. Exelixis, Inc. filed a 10-Q report for the period ending March 29, 2024. T
• EXELIXIS, INC. DEF 14A Filing — DEF 14A · Apr 18, 2024 Risk:
  EXELIXIS, INC. (EXEL) filed a Proxy Statement (DEF 14A) with the SEC on April 18, 2024. The filing is a Definitive Proxy Statement (DEF 14A) for Exelixis, Inc.
• Exelixis Appoints New Chief Medical and Scientific Officers — 8-K · Mar 29, 2024 Risk: medium
  Exelixis, Inc. announced on March 27, 2024, the appointment of Dr. Michelle Werner as Chief Medical Officer and Dr. Peter Lamb as Chief Scientific Officer. Dr.
• Vanguard Holds 18.9% Stake in Exelixis, 60.3M Shares — SC 13G/A · Feb 13, 2024 Risk: low
  The Vanguard Group, a major investment firm, filed an amended SC 13G/A on February 13, 2024, disclosing its ownership of 60,375,540 shares of Exelixis Inc. comm
• Renaissance Technologies Discloses 3.4% Passive Stake in Exelixis — SC 13G · Feb 13, 2024 Risk: low
  Renaissance Technologies LLC, a prominent investment firm, has disclosed a significant passive ownership stake in Exelixis, Inc. (EXEL), a biotechnology company
• EXELIXIS, INC. Files 2023 Annual Report on Form 10-K — 10-K · Feb 6, 2024 Risk:
  EXELIXIS, INC. (EXEL) filed a Annual Report (10-K) with the SEC on February 6, 2024. EXELIXIS, INC. filed its annual report on Form 10-K for the fiscal year end
• BlackRock Amends Exelixis Stake, Files 17th SC 13G/A — SC 13G/A · Jan 24, 2024
  BlackRock Inc. filed an amended SC 13G/A on January 24, 2024, indicating a change in their ownership of Exelixis Inc. common stock as of December 31, 2023. This
• EXELIXIS 8-K: Financial Condition, Officer Comp, Exit Activities — 8-K · Jan 8, 2024
  EXELIXIS, INC. filed an 8-K on January 8, 2024, reporting events that occurred on January 2, 2024. This filing indicates that the company is updating its public

Related Companies

BMY · RHHBY · DSNKY

Frequently Asked Questions